Inhaled mRNA therapy for advanced lung cancer or lung metastases
Part of Cancer clinical trials.
This trial tests an inhaled mRNA immunotherapy for people with advanced lung cancer or solid tumors that have spread to the lungs. It might help if standard treatments no longer work or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced lung cancer (without targetable gene changes or after targeted therapy failed) or tumors that spread to your lungs, and no standard treatments left.
- You have at least one tumor that can be measured on scans.
- You are able to care for yourself and are up and about (ECOG score 0 or 1).
- Your major organs (blood, liver, kidneys) are working well enough.
- Your doctor expects you to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
This trial tests a new mRNA-based treatment injected directly into solid tumors that haven't responded to standard therapy. The goal is to help your immune system recognize and attack cancer cells.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.